Resources from the same session
LBA50 - Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study
Presenter: Jonathan Spicer
Session: Mini oral session 1: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
1209MO - Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159
Presenter: Joshua Reuss
Session: Mini oral session 1: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
LBA49 - Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): Expanded analyses from AEGEAN
Presenter: Martin Reck
Session: Mini oral session 1: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
LBA51 - Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial
Presenter: Andrea Riccardo Filippi
Session: Mini oral session 1: Non-metastatic NSCLC
Resources:
Abstract
Webcast
Invited Discussant LBA49 and LBA51
Presenter: Antonio Calles Blanco
Session: Mini oral session 1: Non-metastatic NSCLC
Resources:
Slides
Webcast
1910MO - ARTIMES: Automated response evaluation to treatment in mesothelioma
Presenter: Kevin Groot Lipman
Session: Mini oral session 1: Non-metastatic NSCLC
Resources:
Abstract
Webcast
1240MO - Quantitative radiomics for the detection of symptomatic pneumonitis following chemoradiotherapy in patients with stage III unresectable NSCLC
Presenter: Jarushka Naidoo
Session: Mini oral session 1: Non-metastatic NSCLC
Resources:
Abstract
Webcast
Invited Discussant 1910MO and 1240MO
Presenter: Jia Wu
Session: Mini oral session 1: Non-metastatic NSCLC
Resources:
Slides
Webcast